BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30858134)

  • 41. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.
    Novello C; Pazzaglia L; Conti A; Quattrini I; Pollino S; Perego P; Picci P; Benassi MS
    PLoS One; 2014; 9(12):e114757. PubMed ID: 25490093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours.
    Mastropasqua F; Marzano F; Valletti A; Aiello I; Di Tullio G; Morgano A; Liuni S; Ranieri E; Guerrini L; Gasparre G; Sbisà E; Pesole G; Moschetta A; Caratozzolo MF; Tullo A
    Mol Cancer; 2017 Mar; 16(1):67. PubMed ID: 28327152
    [TBL] [Abstract][Full Text] [Related]  

  • 43. miR-150, p53 protein and relevant miRNAs consist of a regulatory network in NSCLC tumorigenesis.
    Wang DT; Ma ZL; Li YL; Wang YQ; Zhao BT; Wei JL; Qi X; Zhao XT; Jin YX
    Oncol Rep; 2013 Jul; 30(1):492-8. PubMed ID: 23670238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia.
    Agirre X; Vilas-Zornoza A; Jiménez-Velasco A; Martin-Subero JI; Cordeu L; Gárate L; San José-Eneriz E; Abizanda G; Rodríguez-Otero P; Fortes P; Rifón J; Bandrés E; Calasanz MJ; Martín V; Heiniger A; Torres A; Siebert R; Román-Gomez J; Prósper F
    Cancer Res; 2009 May; 69(10):4443-53. PubMed ID: 19435910
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of transforming growth factor β1 promotes cholangiocarcinoma development and progression.
    Huang CK; Aihara A; Iwagami Y; Yu T; Carlson R; Koga H; Kim M; Zou J; Casulli S; Wands JR
    Cancer Lett; 2016 Sep; 380(1):153-62. PubMed ID: 27364974
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Micro(mi) RNA-34a targets protein phosphatase (PP)1γ to regulate DNA damage tolerance.
    Takeda Y; Venkitaraman AR
    Cell Cycle; 2015; 14(24):3830-41. PubMed ID: 26111201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interplay between PTB and miR-1285 at the p53 3'UTR modulates the levels of p53 and its isoform Δ40p53α.
    Katoch A; George B; Iyyappan A; Khan D; Das S
    Nucleic Acids Res; 2017 Sep; 45(17):10206-10217. PubMed ID: 28973454
    [TBL] [Abstract][Full Text] [Related]  

  • 48. miR-34a is essential for p19(Arf)-driven cell cycle arrest.
    Iqbal N; Mei J; Liu J; Skapek SX
    Cell Cycle; 2014; 13(5):792-800. PubMed ID: 24401748
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A systematic analysis of the 3'UTR of HNF4A mRNA reveals an interplay of regulatory elements including miRNA target sites.
    Wirsing A; Senkel S; Klein-Hitpass L; Ryffel GU
    PLoS One; 2011; 6(11):e27438. PubMed ID: 22140441
    [TBL] [Abstract][Full Text] [Related]  

  • 50. microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status.
    Wang X; Dong K; Gao P; Long M; Lin F; Weng Y; Ouyang Y; Ren J; Zhang H
    Cancer Biother Radiopharm; 2013 Feb; 28(1):45-50. PubMed ID: 23036084
    [TBL] [Abstract][Full Text] [Related]  

  • 51. microRNA-18b modulates insulin-like growth factor-1 expression in deer antler cell proliferation by directly targeting its 3' untranslated region.
    Hu W; Li M; Hu R; Li T; Meng X
    DNA Cell Biol; 2015 Apr; 34(4):282-9. PubMed ID: 25756952
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status.
    Vinall RL; Ripoll AZ; Wang S; Pan CX; deVere White RW
    Int J Cancer; 2012 Jun; 130(11):2526-38. PubMed ID: 21702042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. miR-1299 suppresses cell proliferation of hepatocellular carcinoma (HCC) by targeting CDK6.
    Zhu H; Wang G; Zhou X; Song X; Gao H; Ma C; Chang H; Li H; Liu FF; Lu J; Ma J
    Biomed Pharmacother; 2016 Oct; 83():792-797. PubMed ID: 27490780
    [TBL] [Abstract][Full Text] [Related]  

  • 54. miR-214/199a/199a* cluster levels predict poor survival in hepatocellular carcinoma through interference with cell-cycle regulators.
    Wang P; Chen S; Fang H; Wu X; Chen D; Peng L; Gao Z; Xie C
    Oncotarget; 2016 Jan; 7(1):929-45. PubMed ID: 26498144
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor network.
    Samuel N; Wilson G; Id Said B; Pan A; Deblois G; Fischer NW; Alexandrova R; Casallo G; Paton T; Lupien M; Gariepy J; Merico D; Hudson TJ; Malkin D
    Oncotarget; 2016 Aug; 7(31):49611-49622. PubMed ID: 27391063
    [TBL] [Abstract][Full Text] [Related]  

  • 56. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma.
    Zhao JJ; Lin J; Lwin T; Yang H; Guo J; Kong W; Dessureault S; Moscinski LC; Rezania D; Dalton WS; Sotomayor E; Tao J; Cheng JQ
    Blood; 2010 Apr; 115(13):2630-9. PubMed ID: 20086245
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
    Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
    Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. miR-182 promotes cell growth and invasion by targeting forkhead box F2 transcription factor in colorectal cancer.
    Zhang Y; Wang X; Wang Z; Tang H; Fan H; Guo Q
    Oncol Rep; 2015 May; 33(5):2592-8. PubMed ID: 25738520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MicroRNA-103a-3p controls proliferation and osteogenic differentiation of human adipose tissue-derived stromal cells.
    Kim DS; Lee SY; Lee JH; Bae YC; Jung JS
    Exp Mol Med; 2015 Jul; 47(7):e172. PubMed ID: 26160438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215.
    Georges SA; Biery MC; Kim SY; Schelter JM; Guo J; Chang AN; Jackson AL; Carleton MO; Linsley PS; Cleary MA; Chau BN
    Cancer Res; 2008 Dec; 68(24):10105-12. PubMed ID: 19074876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.